GPER-mediated proliferation and estradiol production in breast cancer-associated fibroblasts

Haojun Luo, Guanglun Yang¹, Tenghua Yu¹, Shujuan Luo², Chengyi Wu¹, Yan Sun³, Manran Liu³ and Gang Tu¹

Department of Breast and Thyroid Surgery, the Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China
¹Department of Endocrine and Breast Surgery, the First Affiliated Hospital of Chongqing Medical University, No. 1 You-Yi Road, Yu-zhong District, Chongqing 400016, China
²Department of Gynecology and Obstetrics, Chongqing Health Center for Women and Children, Chongqing 400010, China
³Key Laboratory of Laboratory Medical Diagnostics, Chinese Ministry of Education, Chongqing Medical University, No. 1 Yi-Xue-Yuan Road, Yu-zhong District, Chongqing 400016, China

Abstract
Cancer-associated fibroblasts (CAFs) are crucial co-mediators of breast cancer progression. Estrogen is the predominant driving force in the cyclic regulation of the mammary extracellular matrix, thus potentially affecting the tumor-associated stroma. Recently, a third estrogen receptor, estrogen (G-protein-coupled) receptor (GPER), has been reported to be expressed in breast CAFs. In this study, GPER was detected by immunohistochemical analysis in stromal fibroblasts of 41.8% (59/141) of the primary breast cancer samples. GPER expression in CAFs isolated from primary breast cancer tissues was confirmed by immunostaining and RT-PCR analyses. Tamoxifen (TAM) in addition to 17β-estradiol (E2) and the GPER agonist G1 activated GPER, resulting in transient increases in cell index, intracellular calcium, and ERK1/2 phosphorylation. Furthermore, TAM, E2, and G1 promoted CAF proliferation and cell-cycle progression, both of which were blocked by GPER interference, the selective GPER antagonist G15, the epidermal growth factor receptor (EGFR) inhibitor AG1478, and the ERK1/2 inhibitor U0126. Importantly, TAM as well as G1 increased E2 production in breast CAFs via GPER/EGFR/ERK signaling when the substrate of E2, testosterone, was added to the medium. GPER-induced aromatase upregulation was probably responsible for this phenomenon, as TAM- and G1-induced CYP19A1 gene expression was reduced by GPER knockdown and G15, AG1478, and U0126 administration. Accordingly, GPER-mediated CAF-dependent estrogenic effects on the tumor-associated stroma are conceivable, and CAF is likely to contribute to breast cancer progression, especially TAM resistance, via a positive feedback loop involving GPER/EGFR/ERK signaling and E2 production.

Key Words
- CAF
- GPER
- tamoxifen resistance
- breast cancer

Introduction
The local microenvironment plays an important and intricate role in the progression of breast cancer. Increasing evidence suggests that activated stroma is a prerequisite for tumor formation (Barcellos-Hoff & Ravani 2000), the progression of ductal carcinoma in situ to the invasive stage (Hu et al. 2008), and the metastatic process.
Endocrine-Related Cancer

In 2000, the ‘rapid’, ‘nongenomic’ effects (Prossnitz & Maggiolini 2009, Owman 1990) of receptors traditionally recognized to mediate rapid signaling in the late 1990s as a seven-transmembrane G-protein-coupled receptor (GPR) were identified by Filardo et al. (2000, Pietras et al. 2005, Revankar et al. 2005). GPER was identified in the late 2000s as a seven-transmembrane G-protein-coupled receptor (GPR) (Prossnitz & Barton 2011). Although the transcriptional effect of estrogen is almost exclusively correlated with ERz, GPER-triggered rapid signaling events have also been observed to regulate gene expression. Multiple genes, such as FOS, BCL2, cyclin D1, connective tissue growth factor (CTGF), and early growth response 1 (EGR1), have been included in the GPER-targeted gene list (Prossnitz & Maggiolini 2009, Madeo & Maggiolini 2010, Vivacqua et al. 2012). Accordingly, GPER has been shown to be involved in the proliferation, migration, chemoresistance, and metastasis of breast cancer (Wang et al. 2010).

Estrogen plays a critical role in the development and cyclic regulation of the mammary gland, which is composed not only of epithelium but also of stroma (Arendt et al. 2010). This raises the logical question of whether estrogen affects breast-cancer-associated stroma. Intriguingly, accumulating evidence related to GPER expression and its proliferative role in breast CAFs has been reported (Madeo & Maggiolini 2010, Pupo et al. 2012, Vivacqua et al. 2012). Madeo & Maggiolini (2010) revealed that GPER is exclusively expressed as an ER in mammary CAFs and induces the expression of C-FOS, cyclin D1, and CTGF in response to E2, confirmed at both the mRNA and the protein level, resulting in the promotion of proliferation. GPER has also been shown to be involved in the growth and migration stimulated by E2, 4-hydroxytamoxifen, and bisphenol A in breast CAFs (Pupo et al. 2012, Vivacqua et al. 2012). Thus, it can be proposed that estrogen, as an important factor in the breast cancer local microenvironment, is involved in cancer progression in a GPER-mediated CAF-dependent model.

Interestingly, tamoxifen (TAM), a selective ER modulator (SERM) targeting ERz, and its metabolite 4-hydroxytamoxifen have been recognized as agonists of GPER (Prossnitz & Barton 2011, Vivacqua et al. 2012), indicating a potential role of GPER in breast cancer TAM resistance. In clinical specimens, the co-expression of ERz (ESR1) and GPER has been found in ~40% of the primary breast cancer cases and GPER expression, as an independent unfavorable factor, has been found to correlate with relapse-free survival in patients treated with TAM (Filardo et al. 2006, Ignatov et al. 2011). In vitro, TAM has been reported to enhance proliferation via sensitivity-enhanced GPER/EGFR/MAPK signaling in TAM-resistant MCF-7 cells, and knockdown of GPR30 in MCF-7 cells has been shown to decrease the proliferation of cells exposed to TAM (Ignatov et al. 2010, Peralta et al. 2010). Furthermore, a TAM analog has been demonstrated to promote...
endometrial cell proliferation and aromatase gene expression, implying that GPER plays a positive role in estrogen production (Lin et al. 2009).

In the present study, we demonstrated that GPER is expressed in the stromal fibroblasts of primary breast cancer tissues and CAFs isolated from tumor tissues. E2, the GPER agonist G1 (1-(4-(6-bromobenzo[1,3]dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl)-ethanone, 1-[3aS,4R,9bR-rel]-4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl]-ethanone), and TAM activated GPER in breast CAFs and promoted proliferation and cell-cycle progression via the GPER/EGFR/ERK axis. Moreover, TAM and G1 induced CYP19A1 gene expression and increased E2 production, also via the GPER/EGFR/ERK pathway, providing novel insights into the estrogenic effects on the breast cancer microenvironment and the induction of TAM resistance in a CAF-dependent manner.

Subjects and methods

Chemicals

E2, TAM, the GPER agonist G1, and the GPER antagonist G15 (4-(6-bromo-benzo[1,3]dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline) were purchased from Sigma–Aldrich. The EGFR inhibitor AG1478 (AG), the ERK1/2 inhibitor U0126, and the PI3K inhibitor Wortmannin (WM) were purchased from Millipore (Temecula, CA, USA). All chemicals were solubilized in DMSO.

Clinical specimens

A total of 141 archival paraffin-embedded, formalin-fixed breast tumor tissue samples were obtained from the Clinical Diagnostic Pathology Center of Chongqing Medical University (Chongqing, China). All patients had undergone surgery at the First Affiliated Hospital of Chongqing Medical University during the period ranging from January 2009 to December 2010. The samples of patients treated with neoadjuvant chemotherapy were excluded. Diagnosis was confirmed by immunohistochemical assays for ERz, progestin receptor, and human EGFR2 by the same center. The investigation was approved by the ethics committee of Chongqing Medical University.

Immunohistochemistry

Commercial rabbit anti-GPER polyclonal antibody (Abcam, Cambridge, MA, USA) was used in immunohistochemical staining as described previously (Filardo et al. 2006). Briefly, tissue samples were deparaffinized and heated at 95 °C in 0.1 mol/l sodium citrate (pH 6.0) for antigen recovery, and endogenous peroxidase activity was quenched with 3% H2O2. Nonspecific binding sites were blocked by incubation in 5% goat serum solution for 30 min at 37 °C. Slides were exposed to primary antibody (1:200) for 2 h at 37 °C. Sections were incubated in HRP-conjugated goat anti-rabbit IgG for 20 min at 37 °C. Diaminobenzidine was added as a substrate. Nuclei were counterstained using Mayer’s modified hematoxylin.

GPER expression in stromal fibroblasts and epithelium was evaluated separately. A specimen was considered to be GPER-positive when distinct staining of at least 10% of the stromal fibroblasts was observed (Hoshino et al. 2011). GPER expression in tumor cells was evaluated as described previously (Filardo et al. 2006).

Isolation, identification, and immortality of mammary fibroblasts and cell culture

 Fibroblasts were isolated as described previously (Zhao et al. 2012). Briefly, tumor tissue samples and coupled grossly normal breast tissue samples (at least 2 cm from the tumor margin) resected during surgery were washed with sterile PBS containing antibiotics (100 U/ml penicillin, 100 μg/ml streptomycin, and 50 μg/ml gentamicin) and were then minced with scissors in a culture dish. After digestion with 0.1% collagenase type I (Sigma) at 37 °C for 8–12 h, the suspensions were carefully pipetted up and down in the culture medium. The suspensions were centrifuged (1200 g for 5 min) and washed with DMEM to remove the fat and tissue debris. The suspension was maintained in DMEM containing 10% fetal bovine serum (FBS) for ~2 days to allow cell attachment. The most adherent cells (fibroblasts) were further maintained in DMEM containing 10% FBS. The investigation was approved by the Local Ethics Committee, and informed consent was obtained from the patients.

CAFs were identified by immunostaining for α-SMA and fibroblast active protein (FAP), as well as by evaluation of cell morphology (Zhao et al. 2012). Fibroblast populations with CAF purity exceeding 85% were used as CAFs in related experiments. The primary CAFs were then immortalized with the human telomerase catalytic subunit (hTERT; from AddGene, Cambridge, MA, USA) for subsequent experiments. MCF-7 cells were maintained in DMEM with phenol red, supplemented with 10% FBS.
Immunofluorescence staining was utilized to identify CAFs and ER expression following a previously described protocol (Zhao et al. 2012). Briefly, 10^5 cells were grown on coverslips for 24 h and fixed with 4% paraformaldehyde, treated with 0.1% Triton X-100, and blocked with 5% goat serum. The cells were then incubated overnight at 4 °C with primary antibodies targeting α-SMA, FAP, and GPER (Abcam) and ERα and ERβ (ZSGB-BIO, Beijing, China); all dilutions were 1:150. After washing with PBS, the cells were stained with a FITC-labeled goat anti-rabbit secondary antibody (1:100; Zhongshan Golden Bridge, Beijing, China) for 10 min and 4',6-diamidino-2-phenylindole (DAPI) for 5 min. Immunofluorescent images were obtained using a Nikon Eclipse 80i microscope (Tokyo, Japan).

Measurement of intracellular Ca^{2+} mobilization

Changes in intracellular Ca^{2+} mobilization were measured using the Ca^{2+}-sensitive fluorescent probe Fluo-3/AM (1-[2-Amino-5-(2,7-dichloro-6-hydroxy-3-oxo-9-xanthenyl)phenoxy]-2-(2-amino-5-methylphenoxy)-ethane-N,N,N',N'-tetraacetic acid, pentaetoxyethyl ester) (Beyotime, Haimen, Jiangsu, China). Cells were seeded in 35 mm dishes for attachment in normal ester) (Beyotime, Haimen, Jiangsu, China). Cells were then incubated overnight at 4 °C with primary antibodies targeting α-SMA, FAP, and GPER (Abcam) and ERα and ERβ (ZSGB-BIO, Beijing, China); all dilutions were 1:150. After washing with PBS, the cells were stained with a FITC-labeled goat anti-rabbit secondary antibody (1:100; Zhongshan Golden Bridge, Beijing, China) for 10 min and 4',6-diamidino-2-phenylindole (DAPI) for 5 min. Immunofluorescent images were obtained using a Nikon Eclipse 80i microscope (Tokyo, Japan).

Measurement of intracellular Ca^{2+} mobilization

Changes in intracellular Ca^{2+} mobilization were measured using the Ca^{2+}-sensitive fluorescent probe Fluo-3/AM (1-[2-Amino-5-(2,7-dichloro-6-hydroxy-3-oxo-9-xanthenyl)phenoxy]-2-(2-amino-5-methylphenoxy)-ethane-N,N,N',N'-tetraacetic acid, pentaetoxyethyl ester) (Beyotime, Haimen, Jiangsu, China). Cells were seeded in 35 mm dishes for attachment in normal ester) (Beyotime, Haimen, Jiangsu, China). Cells were then incubated overnight at 4 °C with primary antibodies targeting α-SMA, FAP, and GPER (Abcam) and ERα and ERβ (ZSGB-BIO, Beijing, China); all dilutions were 1:150. After washing with PBS, the cells were stained with a FITC-labeled goat anti-rabbit secondary antibody (1:100; Zhongshan Golden Bridge, Beijing, China) for 10 min and 4',6-diamidino-2-phenylindole (DAPI) for 5 min. Immunofluorescent images were obtained using a Nikon Eclipse 80i microscope (Tokyo, Japan).

siRNA transfection

CAFs (4×10^5) were seeded into 25 cm^2 culture flasks in 2 ml of growth medium and grown to 80% confluence before transfection. GPER-specific siRNA (siGPER) or nonspecific control siRNA (scrambled siRNA) (Genechem, Shanghai, China) were transiently transected using Lipofectamine 2000 reagent following the manufacturer’s instructions. The target sequences for GPR30 siRNA were 5′-GCUGUA-CAUUUGACGAAAAATT-3′ (A) and 5′-UUUCUGCUCAU-GUACAGCTT-3′ (B). The control siRNA sequence that did not match any known human cDNA was 5′-AAGGTGTGA-GAAGCTGAGAT-3′. GPER protein expression was analyzed by western blotting after transfection.

Real-time RT-PCR

Total RNA was isolated from cells using TRizol (Invitrogen) according to the manufacturer’s protocol. RNA was reverse-transcribed using the RT2 First Strand Kit and MMLV-RT (Takara, Dalian, China). The cDNA was subjected to real-time PCR amplification using genespecific primers and 2× Brilliant II SYBR Green QPCR Master Mix (Invitrogen, La Jolla, CA, USA) as described previously (Zhao et al. 2012). Primer sequences are listed in Table 1. Specific gene expression was calculated using the comparative 2^-ΔΔCt method with GAPDH as the calibrator.

Proliferation assay

Cells were seeded into 96-well plates (5×10^3 cells/well) and cultured for 24 h in normal growth medium. The medium was then replaced with phenol red-free and serum-free medium (DMEM; Gibco), and the cells were cultured for a further 24 h before the addition of E2, G1,
or TAM with or without G15, AG, U0126, and WM pretreatment at the designated concentration. The cells were further cultured in phenol red-free DMEM containing 2.5% dextran-coated charcoal-treated FBS. Cell viability was evaluated using Cell Counting Kit-8 (Beyotime) after 72 h.

**Cell-cycle assay**

Cells were seeded in six-well plates (2×10^5 cells/well) and cultured for 24 h. Cell growth was synchronized in phenol red-free and serum-free medium for 24 h before the addition of E2, G1, or TAM with or without G15, AG, U0126, and WM pretreatment at the designated concentration for 24 h. Cell-cycle distribution was analyzed by flow cytometry as described previously (Liu et al. 2010). Briefly, treated cells were harvested and fixed with 70% ethanol at 4°C for 1 h and then resuspended in 1 ml PBS containing propidium iodide (PI; 50 μg/ml) and RNase A (0.1 mg/ml) and incubated at 37°C for 30 min. Finally, the cells (10^5 cells/analysis) were analyzed by flow cytometry (FACSVantage SE, BD, Franklin Lakes, NJ, USA), and cell-cycle distribution was determined by PI staining of DNA content.

**Immunoblotting**

Cells were stimulated with E2, G1, or TAM for 15 min with or without G15, AG, U0126, and WM pretreatment. Western blotting was then performed as described previously (Liu et al. 2010). Briefly, cell lysates were harvested in a cell lysis buffer (Boster, Wuhan, China), dissolved in 9% SDS–PAGE buffer, and subjected to western blotting using primary detection antibodies against total or phosphorylated ERK1/2 (diluted 1:1000; BioWorld, St Louis Park, MN, USA) and GPER. Membranes were incubated overnight at 4°C before incubation with the appropriate HRP-conjugated secondary antibodies. Immunodetection was conducted using the enhanced chemiluminescence system (Amersham Pharmacia Biotech). Optimal density was analyzed using Image J Software, and results were expressed as fold change relative to the control.

**E2 production assay**

Cells were seeded in six-well plates (2×10^6 cells/well) and cultured to 50% confluence. Testosterone was added at the appropriate concentration. The administration of G1 or TAM was done 1 h later with or without G15, AG, U0126, and WM pretreatment. The cells were cultured for 48 h, and the medium was harvested for E2 detection using the Access E2 Immunoassay System (Beckman Coulter, Brea, CA, USA) in the Endocrinology Laboratory, the First Affiliated Hospital of Chongqing Medical University (Chongqing, China).

**Statistical analysis**

Statistical analysis was carried out using the SPSS System 17.0 for Windows. Associations between GPER expression and clinicopathological determinants were evaluated using the χ² test and the Fisher’s exact test (for nominal variables) as appropriate. For measurement data, Student’s t-test or ANOVAs followed by the Student–Newman–Keuls multiple comparison tests were used to evaluate differences between the subgroups. Two-tailed P values ≤0.05 were considered to be statistically significant.

**Results**

**GPER is expressed in stromal fibroblasts of primary breast cancer tissues**

All the 141 tumor samples included in this study were invasive ductal carcinoma samples from patients who had not received neoadjuvant chemotherapy. The characteristics of patients and tumors are summarized in Table 2. Stromal fibroblasts were identified as large spindle-shaped mesenchymal cells with stress fibers and well-developed fibronexus based on previously reported descriptions (Hoshino et al. 2011). Antibody specificity was validated in SKBr3, MDA-MB-468, MCF-7, MDA-MB-435, and MDA-MB-231 breast cancer cells, which are known to express GPER at varying levels (Supplementary Fig. 1, see section on supplementary data given at the end of the paper).

### Table 1 Real-time PCR primer sequences for genes analyzed

<table>
<thead>
<tr>
<th>Genes</th>
<th>Forward</th>
<th>Reverse</th>
</tr>
</thead>
<tbody>
<tr>
<td>GPER</td>
<td>TGGGGAAGAGGCCACCA</td>
<td>CGTGGAGCTGCTCCT</td>
</tr>
<tr>
<td>ERα</td>
<td>AGGCTAAATCGATCATAC</td>
<td>GAAGCATATGCACAC</td>
</tr>
<tr>
<td>ERβ (ESR2)</td>
<td>AGGCCCTTGCTGACCAAG</td>
<td>AGCGATTCCCTCTCCTC</td>
</tr>
<tr>
<td>CYP19A1</td>
<td>GGCCACATCTCAATACCA</td>
<td>CAGAAGGTGCAACACGTCCA</td>
</tr>
<tr>
<td>GAPDH</td>
<td>GAAGGTGAAGGTCGGAGTC</td>
<td>GAAGATGGTGATGGGATTTC</td>
</tr>
</tbody>
</table>

**E2 production assay**

Cells were seeded in six-well plates (2×10^6 cells/well) and cultured to 50% confluence. Testosterone was added at the appropriate concentration. The administration of G1 or TAM was done 1 h later with or without G15, AG, U0126, and WM pretreatment. The cells were cultured for 48 h, and the medium was harvested for E2 detection using the Access E2 Immunoassay System (Beckman Coulter, Brea, CA, USA) in the Endocrinology Laboratory, the First Affiliated Hospital of Chongqing Medical University (Chongqing, China).

**Statistical analysis**

Statistical analysis was carried out using the SPSS System 17.0 for Windows. Associations between GPER expression and clinicopathological determinants were evaluated using the χ² test and the Fisher’s exact test (for nominal variables) as appropriate. For measurement data, Student’s t-test or ANOVAs followed by the Student–Newman–Keuls multiple comparison tests were used to evaluate differences between the subgroups. Two-tailed P values ≤0.05 were considered to be statistically significant.

**Results**

**GPER is expressed in stromal fibroblasts of primary breast cancer tissues**

All the 141 tumor samples included in this study were invasive ductal carcinoma samples from patients who had not received neoadjuvant chemotherapy. The characteristics of patients and tumors are summarized in Table 2. Stromal fibroblasts were identified as large spindle-shaped mesenchymal cells with stress fibers and well-developed fibronexus based on previously reported descriptions (Hoshino et al. 2011). Antibody specificity was validated in SKBr3, MDA-MB-468, MCF-7, MDA-MB-435, and MDA-MB-231 breast cancer cells, which are known to express GPER at varying levels (Supplementary Fig. 1, see section on supplementary data given at the end of the paper).

### Table 1 Real-time PCR primer sequences for genes analyzed

<table>
<thead>
<tr>
<th>Genes</th>
<th>Forward</th>
<th>Reverse</th>
</tr>
</thead>
<tbody>
<tr>
<td>GPER</td>
<td>TGGGGAAGAGGCCACCA</td>
<td>CGTGGAGCTGCTCCT</td>
</tr>
<tr>
<td>ERα</td>
<td>AGGCTAAATCGATCATAC</td>
<td>GAAGCATATGCACAC</td>
</tr>
<tr>
<td>ERβ (ESR2)</td>
<td>AGGCCCTTGCTGACCAAG</td>
<td>AGCGATTCCCTCTCCTC</td>
</tr>
<tr>
<td>CYP19A1</td>
<td>GGCCACATCTCAATACCA</td>
<td>CAGAAGGTGCAACACGTCCA</td>
</tr>
<tr>
<td>GAPDH</td>
<td>GAAGGTGAAGGTCGGAGTC</td>
<td>GAAGATGGTGATGGGATTTC</td>
</tr>
</tbody>
</table>

**E2 production assay**

Cells were seeded in six-well plates (2×10^6 cells/well) and cultured to 50% confluence. Testosterone was added at the appropriate concentration. The administration of G1 or TAM was done 1 h later with or without G15, AG, U0126, and WM pretreatment. The cells were cultured for 48 h, and the medium was harvested for E2 detection using the Access E2 Immunoassay System (Beckman Coulter, Brea, CA, USA) in the Endocrinology Laboratory, the First Affiliated Hospital of Chongqing Medical University (Chongqing, China).

**Statistical analysis**

Statistical analysis was carried out using the SPSS System 17.0 for Windows. Associations between GPER expression and clinicopathological determinants were evaluated using the χ² test and the Fisher’s exact test (for nominal variables) as appropriate. For measurement data, Student’s t-test or ANOVAs followed by the Student–Newman–Keuls multiple comparison tests were used to evaluate differences between the subgroups. Two-tailed P values ≤0.05 were considered to be statistically significant.

**Results**

**GPER is expressed in stromal fibroblasts of primary breast cancer tissues**

All the 141 tumor samples included in this study were invasive ductal carcinoma samples from patients who had not received neoadjuvant chemotherapy. The characteristics of patients and tumors are summarized in Table 2. Stromal fibroblasts were identified as large spindle-shaped mesenchymal cells with stress fibers and well-developed fibronexus based on previously reported descriptions (Hoshino et al. 2011). Antibody specificity was validated in SKBr3, MDA-MB-468, MCF-7, MDA-MB-435, and MDA-MB-231 breast cancer cells, which are known to express GPER at varying levels (Supplementary Fig. 1, see section on supplementary data given at the end of the paper).
GPER was positively stained in a cytoplasmic pattern, and 59 tumor samples (41.8%) were considered to be stromal fibroblast GPER-positive based on distinct staining of 10% or more of the fibroblasts (Table 2). Two-thirds (66.7%) of the samples exhibited positive tumor cell staining of varying density. Varying degrees of epithelial GPER expression were observed (Fig. 1A, B, C, D, E, F, G and H). However, a significant association was detected between stromal and epithelial GPER expression (data not shown). Interestingly, positive GPER staining was also observed in arterial smooth muscle cells and endothelial cells (Fig. 1I and J), which are considered to be the origins of CAFs (Zeisberg et al. 2007).

Correlations between GPER expression in stromal fibroblasts, as well as in carcinoma cells, and clinicopathological parameters of breast cancer are summarized in Table 2. GPER staining in stromal fibroblasts did not correlate with the determinants analyzed. However, epithelial GPER expression was exclusively associated with ERα expression.

**Table 2** Patient and tumor characteristics

<table>
<thead>
<tr>
<th></th>
<th>No. of patients (%)</th>
<th>GPER positivity</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Parenchymal</td>
<td>Stromal</td>
</tr>
<tr>
<td>Total</td>
<td>141</td>
<td>94</td>
<td>59</td>
</tr>
<tr>
<td>Age (mean±s.d.)</td>
<td>53.0±10.9</td>
<td>53.6±10.9</td>
<td>53.3±11.8</td>
</tr>
<tr>
<td>Menstruation status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Estrous</td>
<td>52 (36.9)</td>
<td>34</td>
<td>20</td>
</tr>
<tr>
<td>Postmenopause</td>
<td>89 (63.1)</td>
<td>60</td>
<td>39</td>
</tr>
<tr>
<td>Tumor size 25.6±13.1</td>
<td></td>
<td>24.4±10.9</td>
<td>26.4±14.8</td>
</tr>
<tr>
<td>&lt;2 cm</td>
<td>58 (41.1)</td>
<td>42</td>
<td>22</td>
</tr>
<tr>
<td>2–5 cm</td>
<td>75 (53.2)</td>
<td>47</td>
<td>32</td>
</tr>
<tr>
<td>&gt;5 cm</td>
<td>8 (5.7)</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>pN(n=134)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>72 (51.1)</td>
<td>50</td>
<td>29</td>
</tr>
<tr>
<td>1</td>
<td>28 (19.9)</td>
<td>19</td>
<td>13</td>
</tr>
<tr>
<td>2</td>
<td>22 (15.6)</td>
<td>12</td>
<td>11</td>
</tr>
<tr>
<td>3</td>
<td>12 (8.5)</td>
<td>8</td>
<td>5</td>
</tr>
<tr>
<td>Staging</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>35 (24.8)</td>
<td>25</td>
<td>14</td>
</tr>
<tr>
<td>II</td>
<td>61 (43.3)</td>
<td>42</td>
<td>25</td>
</tr>
<tr>
<td>III</td>
<td>38 (27.0)</td>
<td>22</td>
<td>19</td>
</tr>
<tr>
<td>X</td>
<td>7 (5.0)</td>
<td>5</td>
<td>1</td>
</tr>
<tr>
<td>Histological grade</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>25 (17.7)</td>
<td>15</td>
<td>12</td>
</tr>
<tr>
<td>2</td>
<td>94 (66.7)</td>
<td>64</td>
<td>36</td>
</tr>
<tr>
<td>3</td>
<td>22 (15.6)</td>
<td>15</td>
<td>11</td>
</tr>
<tr>
<td>NPI (n=134) 4.2±1.2</td>
<td></td>
<td>4.1±1.2</td>
<td>4.3±1.3</td>
</tr>
<tr>
<td>1</td>
<td>13 (9.2)</td>
<td>6</td>
<td>7</td>
</tr>
<tr>
<td>2</td>
<td>36 (26.9)</td>
<td>29</td>
<td>13</td>
</tr>
<tr>
<td>3</td>
<td>63 (44.7)</td>
<td>41</td>
<td>26</td>
</tr>
<tr>
<td>4</td>
<td>22 (15.6)</td>
<td>13</td>
<td>12</td>
</tr>
<tr>
<td>ER + 79 (56.0)</td>
<td>58*</td>
<td>32</td>
<td></td>
</tr>
<tr>
<td>PR + 62 (44.0)</td>
<td>36</td>
<td>27</td>
<td></td>
</tr>
<tr>
<td>PR − 58 (41.1)</td>
<td>40</td>
<td>24</td>
<td></td>
</tr>
<tr>
<td>HER2 + 83 (58.9)</td>
<td>54</td>
<td>35</td>
<td></td>
</tr>
<tr>
<td>HER2 − 67 (47.5)</td>
<td>45</td>
<td>29</td>
<td></td>
</tr>
<tr>
<td>HER2 + 20 (14.2)</td>
<td>13</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>HER2 ++ 31 (22.0)</td>
<td>24</td>
<td>13</td>
<td></td>
</tr>
<tr>
<td>HER2 +++ 23 (16.3)</td>
<td>12</td>
<td>7</td>
<td></td>
</tr>
</tbody>
</table>

*P=0.041. NPI, Nottingham prognostic index.

this article). GPER was positively stained in a cytoplasmic pattern, and 59 tumor samples (41.8%) were considered to be stromal fibroblast GPER-positive based on distinct staining of 10% or more of the fibroblasts (Table 2). Two-thirds (66.7%) of the samples exhibited positive tumor cell staining of varying density. Varying degrees of epithelial GPER expression were observed (Fig. 1A, B, C, D, E, F, G and H). However, a significant association was detected between stromal and epithelial GPER expression (data not shown). Interestingly, positive GPER staining was also observed in arterial smooth muscle cells and endothelial cells (Fig. 1I and J), which are considered to be the origins of CAFs (Zeisberg et al. 2007).

GPER is expressed in CAFs isolated from primary breast cancer tissues

Fibroblasts isolated from primary breast cancer tissues were observed to be myofibroblasts with both a spindle-shaped...
and a stellate morphology. Mammary CAFs were identified by positive staining for α-SMA and FAP as described previously (Zhao et al. 2012; Fig. 2A).

GPER expression was confirmed by immunostaining of primary and immortalized (CAF-hTERT) breast CAFs, using MCF-7 cells as positive controls (Fig. 2A). Moreover, we detected GPER mRNA by real-time RT-PCR in six cases of primary CAFs and immortalized CAFs (Fig. 2B). The level of GPER expression in primary CAFs ranged from 0.08- to 0.98-fold (mean, 0.42-fold) relative to the expression detected in MCF-7 cells. However, GPER expression in CAF-hTERT cells was half (0.49-fold) of that detected in MCF-7 cells. Considering that GPER was identified as a GPCR and overexpressed in MCF-7 cells (Carmeci et al. 1997), GPER expression in breast CAFs was abundant. Notably, the other two ERs, Erα and Erβ, were not detected by immunostaining or quantitative RT-PCR (Fig. 2A and B), consistent with a previous report (Madeo & Maggiolini 2010).

**E2, G1, and TAM stimulate GPER response in breast CAFs**

E2 and TAM have been recognized as agonists of GPER, while G1 has been identified as a selective agonist (Wang et al. 2010, Prossnitz & Barton 2011). The xCELLigence system has been demonstrated to be reliable and sensitive for the analysis of GPCR activation in living cells (Scott & Peters 2010). To confirm the effect of E2, G1, and TAM on GPER in breast CAFs, GPCR activation was monitored dynamically using the xCELLigence system following the administration of these agonists. E2, G1, and TAM stimulated transient and dose-dependent cell index increases within 1 h, with peaking being observed at 1.58 ± 0.21, 1.29 ± 0.11, and 1.31 ± 0.09 respectively. These responses were eliminated by pretreatment with the GPER-specific antagonist G15 (Fig. 3A).

Ca2+ modulation has been reported to be correlated with GPER stimulation (Pietras et al. 2005) and therefore has been utilized as a sensor of GPER activation in early studies (Revankar et al. 2005). We monitored intracellular Ca2+ modulation by labeling laser scanning spectral confocal microscopy analysis of the Fluo-3 AM probe in CAFs. Within 30 s, E2 (1 μM), G1 (1 μM), and TAM (1 μM) enhanced fluorescence intensity (fold changes: 1.41 ± 0.12, 1.29 ± 0.08, and 1.26 ± 0.09, respectively, relative to the baseline), indicating that these agonists stimulated intracellular Ca2+ modulation. Similarly, G15 pretreatment blocked the effects on intercellular Ca2+ stimulated by E2, G1, and TAM (Fig. 3B).

It has been demonstrated that GPER induces ERK1/2 phosphorylation in response to E2 in breast cancer cells (Filardo et al. 2000). We also observed that E2 (1 μM), G1 (1 μM), and TAM (1 μM) stimulated ERK1/2 phosphorylation (fold changes: 1.82 ± 0.22, 1.60 ± 0.19, and 1.59 ± 0.21, respectively, relative to the control). Moreover, G15 pretreatment inhibited ERK1/2 activation induced by GPER ligands in breast CAFs (Fig. 3C).
Although GPER was also detected in fibroblasts isolated from normal breast tissues, no significant effects of E2, G1, and TAM were observed in the aforementioned assays (Supplementary Figs 2 and 3, section supplementary data given at the end of this article).

E2, G1, and TAM promote GPER-mediated proliferation in breast CAFs

The role of GPER in CAF proliferation was examined by the administration of E2, G1, and TAM, and cell viability was measured after treatment for 3 days. E2, G1, and TAM enhanced the proliferation of breast CAFs after culture for 72 h in a dose-dependent manner. Maximal proliferation of 162.7 ± 12.1, 155.8 ± 6.9, and 136.6 ± 8.5% relative to the control was detected following treatment with E2 (10 nM), G1 (1 μM), and TAM (10 nM) respectively (Fig. 4A). G15 abolished these cell proliferative effects (Fig. 4B). To confirm the role of GPER in these proliferative effects further, GPER was knocked down to 39% by specific siRNA transfection of CAFs (CAF-GPERi). Interestingly, none of the ligands stimulated significant proliferative effects in CAF-GPERi cells. Moreover, CAF-GPERi cell numbers were significantly less than CAF-GPER cell numbers following the administration of E2 (10 nM), G1 (1 μM), and TAM (10 nM) (Fig. 4B).

The GPER-mediated effect on cell-cycle progression was investigated. Mammary CAFs were synchronized by estrogen and serum withdrawal and then treated with E2 (10 nM), G1 (1 μM), and TAM (10 nM) for 24 h followed by PI staining and flow cytometry. The administration of E2, G1, and TAM significantly increased the proportion of S-phase CAFs from 13.4 ± 3.2% to 26.9 ± 6.8, 24.7 ± 5.4, and 28.6 ± 4.6%. Importantly, both G15 pretreatment and GPER knockdown blocked the accumulation induced by E2, G1, and TAM (Fig. 4C).
GPER is activated by E2, G1, and TAM in breast CAFs. (A) Cell index was monitored dynamically using the xCELLigence system following the administration of E2, G1, and TAM (concentrations as indicated or 1 μM for all the three agents) at the indicated time (arrow) with or without pretreatment with G15 (1 μM). (B) Ca2+ labeled with the Fluo-3/AM probe was monitored dynamically by laser scanning spectral confocal microscopy. E2 (10 nM), G1 (1 μM), and TAM (10 nM) were added at the indicated time (arrow) with or without G15 (1 μM) pretreatment. (C) CAFs were treated with E2 (10 nM), G1 (1 μM), and TAM (10 nM) for 15 min, with or without G15 (1 μM) pretreatment. Cell extracts were used for immunoblotting analysis of total and phosphorylated ERK1/2. Results are shown as fold changes in optimal density compared with the control (−). *P<0.05, vs control; open square, open circle, and filled circle, P<0.05, between the two marked groups.

GPER/EGFR/ERK pathway is involved in TAM-induced CAF proliferation

As has been mentioned previously, GPER stimulation is involved in the transactivation of EGFR/ERK signaling and PI3K modulation in breast cancer cells (Filardo et al. 2002, Revankar et al. 2005). In this study, G15 (selective GPER antagonist), AG, U0126, and WM (inhibitors of EGFR, ERK1/2, and PI3K respectively) were used to evaluate the role of these pathways in GPER-mediated proliferation and cell-cycle changes in breast CAFs. G15, AG, and U0126 significantly inhibited the proliferation induced in CAFs by G1, TAM (Fig. 5A), and E2 (data not shown). WM treatment had no significant influence on CAF proliferation (Fig. 5A). Similar trends were observed for the accumulation of S-phase cells in response to G1, TAM (Fig. 5B), and E2 (data not shown). As a sensor of GPER/EGFR/ERK signaling activation, ERK1/2 phosphorylation was detected by immunoblotting. As expected, G15, AG, and U0126 significantly reduced ERK1/2 phosphorylation induced by G1, TAM (Fig. 5C), and E2 (data not shown) in CAFs. However, WM treatment had no significant influence on ERK1/2 phosphorylation in CAFs (Fig. 5C). Moreover, these GPER ligands did not enhance ERK phosphorylation in CAF-GPERi cells (Fig. 5D).

GPER is involved in TAM-induced E2 production

CAFs are known to be an important source of local estrogen in breast cancer (Yamaguchi & Hayashi 2009). We tested the ability of CAFs to synthesize E2 in vitro. The substrate of E2, testosterone, was added to the CAF culture medium for 48 h before harvesting for E2 detection by chemiluminescence immunoassay. The administration of testosterone stimulated dose-dependent E2 production. Furthermore, at a dose of 10 mM testosterone, the S-phase accumulation increased dramatically to 44±5.8% (vs 32.3±4.5% in the control), while the concentration of E2 increased to 1553±158 pg/ml (vs 74±11 in the control) (Fig. 6A).

Increasing evidence indicates that GPER is involved in aromatase gene regulation and local estrogen production (Lin et al. 2009, van Duursen et al. 2011, Pupo et al. 2012). We evaluated the potential role of GPER and related signaling in E2 production in the breast microenvironment. Interestingly, GPER activation increased E2 production in breast CAFs. Treatment of CAFs with testosterone (100 nM) stimulated the production of 286±36 pg/ml (vs 73±14 pg/ml in the control) of E2 after cultivation for 48 h. The administration of TAM (10 nM) and G1 (1 μM) further increased the...
concentration of E2 to 419±60 and 541±69 pg/ml respectively. This enhancement was inhibited by GPER knockdown and G15, AG, and U0126 administration but not by WM administration (Fig. 6C). These data were paralleled by the effects of GPER interference and G15, AG, U0126, and WM on cell viability when administered under identical conditions (Fig. 5B). Hence, we attempted to verify whether this phenomenon was caused by GPER-mediated proliferation or GPER-induced aromatase expression in breast CAFs (Lin et al. 2009, van Duursen et al. 2011, Pupo et al. 2012). As expected, culturing with TAM (10 nM) and G1 (1 μM) for 18 h induced CYP19A1 gene expression (fold changes: 3.4±0.6 and 3.8±1.0, respectively, vs the control) in CAFs, and this effect was blocked by GPER interference and G15, AG, and U0126 but not by WM (Fig. 6D).

Discussion

Estrogens play an important role in breast cancer development. ERα is widely accepted as a target for endocrine therapy of breast cancer, and a well-known SERM, TAM, provides considerable benefits for patients with breast cancer at different stages. However, acquired TAM resistance in ERα-positive breast cancer cells has become a significant challenge in its clinical application. Recently, TAM resistance has been reported to be correlated with the expression of the novel ER, GPER (Ignatov et al. 2010, 2011). In the present study, we demonstrated that GPER is expressed in the stromal fibroblasts of primary breast cancer tissues and CAFs isolated from tumor tissues. TAM, in addition to E2 and the GPER agonist G1, promoted proliferation, cell-cycle progression, and E2 production via the GPER/EGFR/ERK axis in breast CAFs, providing novel insights into the GPER-mediated CAF-dependent mechanism of TAM resistance in breast cancer.

GPER was first detected as a GPCR gene in breast cancer cell lines as well as in primary breast cancer in 1997 (Carmeci et al. 1997). Subsequently, several examples of GPER expression in breast cancer have been reported. Filardo et al. (2006) conducted an immunohistochemical analysis of the distribution of GPER in 361 cases of breast cancer and correlated GPER with the expression of ERα, the progestin receptor, and human EGFR2 as well as tumor size and the presence of metastasis. However, results obtained in other studies were not consistent with these observations (Tu et al. 2009, Arias-Pulido et al. 2010, Ignatov et al. 2011). In the present study, the presence of GPER in cancer cells was exclusively correlated with ERα...
expression (Table 2). Additionally, the co-expression of GPER and ERα in carcinoma cells was found in 41.1% of all samples, which is in accordance with previous reports (Filardo et al. 2006, Tu et al. 2009, Ignatov et al. 2011). The presence of ERα is considered to be a definite indication for the administration of TAM, which is a well-characterized agonist of GPER. TAM administration has been shown to stimulate GPER in these patients, resulting in proliferative effects (Lin et al. 2009, Madeo & Maggioni 2010, Pupo et al. 2012, Vivaquaa et al. 2012). In vitro, TAM has been reported to promote proliferation via sensitivity-enhanced GPER/EGFR/MAPK signaling in TAM-resistant MCF-7 cells (Ignatov et al. 2010, Peralta et al. 2010). In recent follow-up studies, GPER has been shown to be correlated with reduced relapse-free survival in patients undergoing TAM treatment (Ignatov et al. 2011). These observations implicate GPER in breast carcinoma TAM resistance, although this remains to be confirmed.

GPER has been detected in stromal inflammatory cells, myoepithelium, and fibroblasts in addition to tumor cells of primary breast cancer (Arias-Pulido et al. 2010), although an analysis of its expression has not been reported previously. In this study, positive GPER staining was observed in stromal fibroblasts, smooth muscle cells, and arterial endothelial cells, all of which are recognized as origins of CAFs (Karnoub et al. 2007, Xing et al. 2010, Cirri & Chiarugi 2012). Considering the important role of both estrogen and CAFs in breast cancer development, we correlated GPER expression in stromal fibroblasts with the clinicopathological determinants of breast cancer. Although no significant association was found, GPER expression was definitely detected in stromal fibroblasts of 41.8% of the samples (Table 2), implying a GPER-mediated CAF-dependent estrogenic effect in tumor microenvironment.

Estrogens play an important role in the development of mammary glands and associated carcinomas. In healthy women, the extracellular matrix of breast tissue, in addition to the mammary epithelial cells, undergoes cyclic changes with each menstrual cycle (Arendt et al. 2010). Although stromal ERα has been demonstrated to be critical for breast
development in mice (Mueller et al. 2002), studies focusing on ERs and estrogen effects in tumor-associated stroma are rare. Recently, GPER has been demonstrated to be a unique ER mediating E2-stimulated proliferation and migration of breast CAFs (Madeo & Maggiolini 2010). Subsequently, GPER/EGFR/ERK signaling has been claimed to upregulate the expression of EGR1, CTGF, C-FOS, and cyclin D1, resulting in proliferation enhancement in mammary CAFs (Pupo et al. 2012, Vivacqua et al. 2012). Interactions between estrogen and growth factors were delineated decades ago (Pietras et al. 2005). GPER is thought to be largely responsible for this crosstalk, as it has been demonstrated to employ the EGFR/ERK pathway as its predominant signaling pathway, and growth factors including EGF, CTGF, transforming growth factor α/β, and insulin-like growth factor have been observed to regulate GPER expression or be regulated by GPER activation (Filardo 2002, Filardo et al. 2002, Vivacqua et al. 2009, Madeo & Maggiolini 2010, De Marco et al. 2012). Similarly, we demonstrated in this study that...
GPER/EGFR/ERK signal transduction mediates E2-induced proliferation in breast CAFs, based on the observation that G1 induced similar proliferative and cell-cycle promotion that was blocked not only by GPER interference but also by G15, AG, and U0126 administration. These observations revealed the CAF-dependent estrogenic effects on breast cancer microenvironment.

Interestingly, we demonstrated that TAM also stimulated the proliferation of CAFs via the GPER/EGFR/ERK pathway in this study (Fig. 5), and its metabolite 4-hydroxytamoxifen has also been shown to promote breast CAF growth in a previous study (Vivacqua et al. 2012). Notably, ~40% of ERα-positive tumors expressed GPER in stromal fibroblasts in our study (Table 2). CAFs are promoters of tumor growth; therefore, it can be suggested that the anti-estrogen effect of TAM in tumor cells is negated by TAM-induced proliferation in CAFs, resulting in acquired TAM resistance in these patients. Recently, GPER expression in breast cancer cells has been reported to be correlated with poorer relapse-free survival only in patients treated with TAM, but tended to be a favorable factor in patients who did not receive TAM therapy (Ignatov et al. 2011). A potential role for GPER expression in CAFs in this bidirectional effects is indicated by the detection of stromal fibroblast GPER expression in 40% of ERα-positive tumors in our study. Thus, more follow-up data are required in addition to an analysis of GPER expression in stromal fibroblasts and epithelium as determinants for TAM administration in breast cancer patients.

CAFs are an important source of local estrogen, which is an important mediator of breast cancer progression (Yamaguchi & Hayashi 2009). As a key enzyme involved in estrogen synthesis, aromatase has become a paradigm target of endocrine therapy in breast cancer patients. Intriguingly, GPER has been reported to be correlated with aromatase gene upregulation directly or indirectly in previous studies (van Duursen et al. 2011, Pupo et al. 2012). An analog and a metabolite of TAM have been demonstrated to promote aromatase gene expression via GPER activation in endometrial cancer cells (Lin et al. 2009). Furthermore, genistein, a well-recognized GPER agonist, has been reported to increase breast-cancer-associated aromatase expression and activity in vitro (van Duursen et al. 2011). In the present study, TAM and G1 increased both CYP19A1 mRNA and E2 production in CAFs, and this effect was dependent on GPER/EGFR/ERK pathway signaling. Taken together, these observations indicate that GPER in breast CAFs is involved in the increased local production of E2, thus presenting a feed-forward loop model that has been postulated to contribute to TAM resistance in breast cancer patients.

The role of GPER in breast CAFs warrants further investigation following its detection in stromal fibroblasts in breast cancer tissues. Furthermore, we confirmed previous reports that the GPER/EGFR/ERK pathway contributes to the proliferation of breast CAFs (Madeo & Maggiolini 2010, Pupo et al. 2012, Vivacqua et al. 2012). Thus, our data provide new insights into estrogenic effects on tumor microenvironment. More importantly, TAM, which is commonly accepted to be a SERM for breast cancer patients, was shown to stimulate proliferation and E2 production in breast CAFs. Hence, GPER is implicated in TAM resistance in a CAF-dependent manner. As such, GPER expression in stromal fibroblasts would be considered a contra-indicator of TAM application or additional therapy targeting GPER signaling ought to be offered in the future.

Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/ERC-13-0237.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This study was supported by the National Natural Science Foundation of China (NSFC 81372398, NSFC 81072149, and NSFC 81072147).

Acknowledgements
The authors thank Prof. Hua Tang from the Key Laboratory of Molecular Biology for Infectious Diseases, Ministry of Education Medicine, Chongqing Medical University, for his kind help.

References


Received in final form 23 January 2014
Accepted 30 January 2014
Made available online as an Accepted Preprint 30 January 2014